4 recruiting, 3 completed. 3 Phase 1, 1 Not applicable, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Recruiting 2, Completed 1 |
| Not applicable | 1 | Completed 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Relay Therapeutics, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors RLY-8161 - Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors | Phase 1 | Recruiting | Relay Therapeutics, Inc. | 35 | 2026-03-09 | 2026-07-02 |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer Zovegalisib, Capivasertib, Fulvestrant - PIK3CA Mutation, HER2- Negative Breast Cancer | Phase 3 | Recruiting | Relay Therapeutics, Inc. | 540 | 2025-08-26 | 2026-10-05 |
| A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study) RLY-2608, Placebo - PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations | Phase 2 | Recruiting | Relay Therapeutics, Inc. | 277 | 2025-06-13 | 2026-08-25 |
| First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors RLY-5836, Fulvestrant, Palbociclib - PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Completed | Relay Therapeutics, Inc. | 41 | 2023-03-29 | 2025-05-16 |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer RLY-2608, Fulvestrant, Palbociclib 125mg - PIK3CA Mutation, Solid Tumor, Adult | Phase 1 | Recruiting | Relay Therapeutics, Inc. | 930 | 2021-12-08 | 2025-09-22 |
| A Study to Assess Virtual Reality by Healthcare Providers: A Pilot Study Random assigned paradigm viewing order - Anxiety, Burn Out | Not applicable | Completed | Mayo Clinic | 24 | 2021-01-01 | 2024-01-02 |
| Early Childhood Obesity Programming by Intrauterine Growth Restriction Childhood Obesity, Epigenetics | Completed | Montefiore Medical Center | 163 | 2018-09-01 | 2026-08-31 |
Breast Neoplasms (3) · Anxiety Disorders (1) · Burnout, Psychological (1) · Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi (1) · Klippel-Trenaunay-Weber Syndrome (1) · Lymphatic Abnormalities (1) · Megalencephaly cutis marmorata telangiectatica congenita (1) · Pediatric Obesity (1) · Vascular Malformations (1)
Fulvestrant (3) · palbociclib (2) · ribociclib (2) · abemaciclib (1) · capivasertib (1)
United States (7) · Australia (3) · France (3) · Italy (3) · Spain (3) · Belgium (2) · Germany (2) · Ireland (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Bulgaria (1) · Canada (1) · Czechia (1)
Brent Bauer, MD (1) · Ivana T Croghan, PhD (1) · Sandra Reznik, MD (1)
PMID 35352605, PMID 38059784, PMID 38997672
R01HD092533 (1), R16GM145586 (1), S10OD030286 (1)